5 Key Takeaways
-
1
Ellipsoid zone integrity is now an FDA-supported clinical trial endpoint for dry age-related macular degeneration (AMD).
-
2
The measurement of ellipsoid zone to retinal pigment epithelium distance is crucial for assessing total ellipsoid zone loss.
-
3
Machine learning segmentation platforms can effectively analyze OCT scans to predict geographic atrophy progression in intermediate dry AMD.
-
4
Recent trials indicate that ellipsoid zone changes correlate with visual function and can predict future vision loss in AMD patients.
-
5
The ReCLAIM-2 trial demonstrated significant reductions in ellipsoid zone loss with elamipretide treatment, highlighting its potential as a trial endpoint.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.